Alector, INC Form 4 insider transactions

Alector's Chief Financial Officer, Marc Grasso, sold 7,297 shares of common stock on September 3, 2024, to satisfy tax obligations related to vesting restricted stock units.

Alector's CEO, Arnon Rosenthal, sold 26,499 shares of common stock on September 3, 2024, to cover tax obligations related to vesting restricted stock units.

Sara Kenkare-Mitra, President and Head of R&D at Alector, Inc., sold 13,926 shares of common stock on September 3, 2024, to satisfy tax obligations related to vesting restricted stock units.

Gary Romano, Chief Medical Officer of Alector, Inc., sold shares of common stock on September 3, 2024, to satisfy tax obligations related to vesting restricted stock units.

Richard H. Scheller, a director at Alector, Inc., sold 44,250 shares of common stock on August 22, 2024, at an average price of $5.1613.

Director Paula Hammond sold 10,500 shares of Alector, Inc. common stock on August 12, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Kristine Yaffe sold 5,000 shares of Alector, Inc. common stock at an average price of $5.0618 on August 12, 2024, according to a Form 4 filing.

Director Louis J Lavigne Jr. acquired 35,000 shares of Alector, Inc. common stock on June 12, 2024, through restricted stock units.

Director Kristine Yaffe acquired 35,000 restricted stock units in Alector, Inc.

Director Elizabeth A. Garofalo acquired 35,000 shares of Alector, Inc. common stock on June 12, 2024, through restricted stock units.

Director Richard H. Scheller acquired 35,000 shares of Alector, Inc. common stock on June 12, 2024, through restricted stock units.

Director David M. Wehner acquired 35,000 shares of Alector, Inc. common stock on June 12, 2024, through restricted stock units.

Director Paula Hammond acquired 35,000 shares of Alector, Inc. common stock on June 12, 2024, through restricted stock units.

Gary Romano, Chief Medical Officer of Alector, Inc., sold 8,040 shares of common stock on June 3, 2024, to satisfy tax obligations related to vesting restricted stock units.

Sara Kenkare-Mitra, President and Head of R&D at Alector Inc., sold shares of common stock on June 3, 2024, to cover tax obligations related to vesting restricted stock units.

Alector's CEO, Arnon Rosenthal, sold shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Alector's Chief Financial Officer, Marc Grasso, sold shares of common stock on June 3, 2024, to satisfy tax obligations related to the vesting of restricted stock units.

Polaris Venture Management Co. VI, L.L.C. distributed Alector, Inc. shares pro-rata to its limited partners and members on May 29, 2024, resulting in changes in beneficial ownership.

Polaris Venture Management Co. VI, L.L.C. and affiliated funds distributed Alector, Inc. (ALEC) shares pro-rata to its members, reflecting a change in ownership form rather than a purchase or sale.

Director Mark Altmeyer of Alector, Inc. acquired stock options and restricted stock units (RSUs) on March 19, 2024.

Director Errol B Desouza acquired shares and stock options in Alector, Inc. on March 19, 2024.

Alector's Chief Financial Officer, Marc Grasso, sold shares of common stock on March 4, 2024, to satisfy tax obligations related to the vesting of restricted stock units.

Alector's CEO, Arnon Rosenthal, sold 18,837 shares of common stock on March 4, 2024, to satisfy tax obligations related to vesting restricted stock units.

Gary Romano, Chief Medical Officer of Alector, Inc., sold 6,001 shares of common stock on March 4, 2024, to satisfy tax obligations related to vesting restricted stock units.

Sara Kenkare-Mitra, President and Head of R&D at Alector Inc., sold shares of common stock on March 4, 2024, to cover tax obligations related to vesting restricted stock units.